crisnatol mesylate

An anticancer drug that interferes with the DNA in cancer cells.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
This Phase I and pharmacological study was performed to assess the feasibility of administering the polycyclic aromatic… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1997
1997
A total of 26 patients (6 with anaplastic astrocytoma; 20 with glioblastoma) were treated with crisnatol mesylate. All patients… (More)
Is this relevant?
1992
1992
Fourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate… (More)
  • table 2
Is this relevant?
1992
1992
Microbial metabolism studies of crisnatol (1), a new DNA interca-lator, has resulted in the isolation and characterization of a… (More)
Is this relevant?
1991
1991
Crisnatol mesylate is a rationally designed cytotoxic arylmethylamino-propanediol with broad spectrum cytotoxic activity. A phase… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
1990
1990
The pharmacodynamics of a new series of antitumor DNA intercalators, known as arylmethylaminopropanediols (AMAPs), has been… (More)
Is this relevant?